C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma Life Science Investing
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference Life Science Investing
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer Life Science Investing
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Life Science Investing
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference Life Science Investing
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option Life Science Investing
Doseology Appoints Larry Latowsky as Executive Chairman of the Board of Directors Life Science Investing
Doseology Appoints Larry Latowsky as Executive Chairman of the Board of Directors Life Science Investing
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer
